19:17 , Apr 12, 2019 |  BC Week In Review  |  Company News

Ascentage, Junshi to evaluate APG-1387-toripalimab combo for cancer

Ascentage and Junshi partnered to conduct clinical trials in China evaluating APG-1387 in combination with Tuoyi toripalimab to treat solid tumors and hematological cancers. Ascentage Pharma Group Corp. Ltd. (Suzhou, China) declined to disclose details,...
20:40 , Jan 18, 2019 |  BC Week In Review  |  Company News

MD Anderson collaborating with Ascentage, Nanobiotix on clinical testing of cancer assets

The University of Texas MD Anderson Cancer Center unveiled two new partnerships with China's Ascentage Pharma Group International (Suzhou, China) and France's Nanobiotix S.A. (Euronext:NANO) for clinical testing of their respective cancer assets. MD Anderson's...
22:44 , Jan 7, 2019 |  BC Extra  |  Politics & Policy

Bipartisan bill to streamline U.S. response to foreign theft of IP may hasten clarity on biotech impact

As the biopharma industry awaits guidance from the government on the scope and potential impact of proposed technology export controls, a new congressional bill could help speed the process. Members of the Senate Select Committee...
02:49 , Jan 5, 2019 |  BioCentury  |  Finance

Ready to launch

  The proposed $74 billion takeout of Celgene Corp. by Bristol-Myers Squibb Co. will not shift buysider attention away from upcoming and maturing drug launches heading into 2019, with plenty to track following a record...
04:43 , Dec 15, 2018 |  BioCentury  |  Product Development

O’Day’s expansive task at Gilead

A fresh executive team and a track record of building deep portfolios could allow incoming Gilead Sciences Inc. chairman and CEO Daniel O’Day to do what his predecessors couldn’t: make Gilead a leader outside of...
19:20 , Nov 19, 2018 |  BC Extra  |  Financial News

NASH company Genfit planning U.S. listing

As it prepares for a readout from a Phase III study of its lead candidate to treat non-alcoholic steatohepatitis, French bellwether Genfit S.A. (Euronext:GNFT) intends to conduct a listing on a U.S. exchange. Genfit said...
16:16 , Oct 4, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Breast cancer; leukemia Cell culture, mouse and patient-derived organoid studies identified a benzothiophene-benzothiazole-based BIRC2 inhibitor that could help treat breast cancer and leukemias. Screening of 50,000 small molecules in BIRC2 enzymatic activity assays yielded...
18:12 , Jun 1, 2018 |  BC Week In Review  |  Clinical News

Ascentage reports Phase I safety data for IAP inhibitor in solid tumors

Ascentage Pharma Group Corp. Ltd. (Hong Kong, China) said IV APG-1387 once every week for three out of four weeks in each 28-day cycle was well tolerated with manageable adverse events in 28 evaluable patients...
19:17 , Apr 13, 2018 |  BC Week In Review  |  Company News

CIRM launches industry partnership network for its stem cell projects

The California Institute for Regenerative Medicine (CIRM) launched its Industry Alliance Program (IAP) to secure industry partnerships and funding for its stem cell research projects. IAP will connect pharma, biotech and VC firms with CIRM-funded...
15:03 , Mar 1, 2018 |  BC Innovations  |  Translation in Brief

A path less traveled

A team from PSL Research University has shown how a nitric oxide (NO)-donating compound steers TNFα signaling away from a pro-survival pathway towards one that promotes death in cancer cells. The findings suggest NO-donors could...